Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766

By Adis International Limited  

Drugs in R&D, Vol. 7, Iss. 5, 2006-01 ,pp. : 317-328

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis ® ) in Cancer Patients

By Juan Jose Perez-Ruixo   Zannikos Peter  

Clinical Pharmacokinetics, Vol. 46, Iss. 10, 2007-01 ,pp. : 867-884

Adis International

Access to resources Recommend Favorite

Trabectedin (Yondelis^TM, formerly ET-743), a mass balance study in patients with advanced cancer

By Beumer J.   Rademaker-Lakhai J.   Rosing H.   Lopez-Lazaro L.   Beijnen J.   Schellens J.  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 429-436

Springer Publishing Company

Access to resources Recommend Favorite

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

By Beumer Jan-Hendrik   Buckle Tessa   Ouwehand Mariet   Franke Niels   Lopez-Lazaro Luis   Schellens Jan   Beijnen Jos   Tellingen Olaf  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Ecteinascidin 743 [ET-743] may play an important role in the treatment of soft tissue sarcomas and other cancers

By  

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite